Pfizer (PFE)
Pfizer Cash Investing: 451.00M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PFE Cash Investing Rankings
| Overall | 98th percentile | 45 of 4330 |
| Sector | 99th percentile | 3 of 500 in Healthcare |
| Industry | 88th percentile | 3 of 25 in Drug Manufacturers - Major |
PFE Cash Investing Range, Past 5 Years
| Minimum | -13.63B | Mar 2009 |
| Maximum | 9.394B | Mar 2010 |
| Average | -2.271B |
About Cash Investing
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from investing activities. Includes the company's cash inflows and outflows from investments in financial markets and the sale of capital assets.
Learn More
You may also be interested in these PFE related companies
PFE News
$AMRN I would be surprised if $PFE isn't having backchannel talks pre-889.$AMRN is a perfect takeout...very few employees and cinch approval
about 7 hours ago by InTheBarn
about 7 hours ago by InTheBarn
Drug Stocks In The Spotlight At ASCO Conference. $JNJ $CELG $ONXX $RHHBY $PFE http://stks.co/42e8
about 17 hours ago by abubnic
about 17 hours ago by abubnic
@SciGuy $DRRX I don't believe so; the fortunes of DURECT are tied to $PFE and Remoxy
about 20 hours ago by SlownSteady
about 20 hours ago by SlownSteady
@SCarolinaguy $DRRX licensed the drug to $PTIE; $PTIE licensed it to King and $PFE bought King; I think people might forget about $DRRX
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SlownSteady Sounds encouraging with $PFE supporting. What is the relationship? Surely their support would lead to approval
about 21 hours ago by SCarolinaguy
about 21 hours ago by SCarolinaguy
@SCarolinaguy $DRRX $PFE plans to resubmit the NDA. The company has other products; a recent filed trial triggered share price punishment
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SCarolinaguy $DRRX Only insiders know. CMC problems are usually resolved. $PFE will have new data and meet with the FDA
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
RT @Glopolon: Does it matter, they are next door to $PFE $AMRN /i live next to a lawyer. odds of being sued increased day they moved in. Hmm
about 4 days ago by ITradeforMe
about 4 days ago by ITradeforMe
RT @Glopolon $AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404L <Hmmmmmmmm!?$$$
about 4 days ago by Bleedblue
about 4 days ago by Bleedblue
$AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404H
about 4 days ago by Glopolon
about 4 days ago by Glopolon
@SomeGuy900 @christy155 $DRXX If $PFE gets a class 2 resubmission, they'll know in Q2/Q3 of next year; class one they'll know in Q1/Q2 '13
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRXX The $PFE discussions with the FDA should be in Q3; I imagine they will resubmit in early 2013
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 The last comment from $DRRX management was that $PFE was getting ready to talk to the FDA about some more studies
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRRX I have no idea what's going on. It's gone up 20 cents since I bought in. Maybe $PFE will talk with the FDA
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 21.87 | -0.17 | -0.77% | 166.12B |
| PETM | 64.47 | +0.02 | +0.03% | 7.082B |
| PETD | 24.80 | +0.06 | +0.22% | 584.84M |
| PERY | 18.82 | -0.07 | -0.37% | 296.95M |
| PERI | 3.86 | -0.19 | -4.69% | 40.18M |
| PERF | 7.80 | -0.01 | -0.13% | 70.06M |
| PER | 19.93 | -0.07 | -0.35% | 787.60M |
| PEP | 67.99 | -0.23 | -0.34% | 108.30B |
| PEOP | 16.08 | +0.33 | +2.10% | |
| PEO | 23.01 | -0.18 | -0.78% |